Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

T2705

Sigma-Aldrich

Topotecan hydrochloride hydrate

≥98% (HPLC and enzymatic), powder, topoisomerase I inhibitor

Sinónimos:

9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin hydrochloride hydrate, NSC-609669 hydrochloride hydrate, SKF-104864A hydrochloride hydrate, hycamptamine hydrochloride hydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C23H23N3O5 · xHCl · yH2O
Número de CAS:
123948-87-8
Peso molecular:
421.45 (anhydrous free base basis)
Número MDL:
MFCD00870670
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
329826724
NACRES:
NA.77

Nombre del producto

Topotecan hydrochloride hydrate, ≥98% (HPLC and enzymatic)

Nivel de calidad

100

Ensayo

≥98% (HPLC and enzymatic)

Formulario

powder

condiciones de almacenamiento

desiccated
protect from light

color

yellow

solubilidad

DMSO: ≥20 mg/mL

emisor

GlaxoSmithKline

temp. de almacenamiento

−20°C

cadena SMILES

[n]21c(cc5c([c]2=O)COC(=O)[C@]5(O)CC)c3nc4c(cc3C1)c(c(cc4)O)CN(C)C

InChI

1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1

Clave InChI

UCFGDBYHRUNTLO-QHCPKHFHSA-N

Información sobre el gen

human ... TOP1MT(116447)

Aplicación

Topotecan has been used as a positive control for the identification and analysis of HIF-1α and VEGF inhibitors in human glioma cells under hypoxic conditions1. It has also been used for in vitro apoptosis assays in PA317 cells2.

Acciones bioquímicas o fisiológicas

Topotecan is a topoisomerase I inhibitor and an apoptosis inducer. It is a potent antineoplastic agent.

Características y beneficios

This compound is a featured product for ADME Tox and Apoptosis research. Discover more featured ADME Tox and Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Nota de preparación

This product is soluble in water, however, the concentration has not been determined. Various sources state this chemical can be solubilized in water at greater than 1 mg/mL.
Topotecan hydrochloride hydrate is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

Pictogramas

Health hazard
GHS08

Palabra de señalización

Danger

Frases de peligro

H340,H361d

Clasificaciones de peligro

Muta. 1B - Repr. 2

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000314301
0000314301
0000239575
0000218334
0000195682

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ian F King et al.
Nature, 501(7465), 58-62 (2013-09-03)
Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor
Andrei Molotkov et al.
Pharmaceutics, 13(3) (2021-04-04)
Glioblastoma (GBM) is the most common primary adult brain malignancy with an extremely poor prognosis and a median survival of fewer than two years. A key reason for this high mortality is that the blood-brain barrier (BBB) significantly restricts systemically
Jerec W Ricci et al.
Molecular cancer therapeutics, 15(12), 2853-2862 (2016-09-28)
Chemotherapeutic resistance remains a challenge in the treatment of ovarian carcinoma, especially in recurrent disease. Despite the fact that most patients with newly diagnosed tumors attain complete remission following cytoreductive surgery and chemotherapy, ovarian carcinoma has a recurrence rate that
Iben Kümler et al.
Breast cancer research and treatment, 138(2), 347-358 (2013-03-21)
Following treatment with anthracyclines and taxanes, few established options exist for the treatment of metastatic breast cancer (MBC). Although the topoisomerase 1 inhibitors irinotecan, etirinotecan, and topotecan have been used in clinical trials on MBC, the drugs have never been
Israel Zighelboim et al.
Gynecologic oncology, 130(1), 64-68 (2013-04-18)
We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior
Ver todos los artículos relacionados

Artículos

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Ver todo

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico